---
schema_version: "secwatch.filing_event.v1"
accession: "0001447362-23-000007"
form_type: "8-K"
ticker: "CSTL"
cik: "0001447362"
company_name: "CASTLE BIOSCIENCES INC"
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:40:45.259246+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Castle Biosciences expects 2022 revenue to exceed top end of $132-137M guidance

## Summary
- Total test reports in 2022: 44,338, up 58% YoY from 28,118.
- DecisionDx-Melanoma volume 27,797 (+37% YoY); DecisionDx-SCC 5,966 (+70% YoY).
- Year-end cash & short-term investments ~$259M ($123M cash + $136M short-term).
- Q4 2022 test reports 12,563 (+52% YoY from 8,242); TissueCypher and IDgenetix newly contributed.

## SEC filing metadata
- accession: 0001447362-23-000007
- form_type: 8-K
- ticker: CSTL
- cik: 0001447362
- company_name: CASTLE BIOSCIENCES INC
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447362/000144736223000007/0001447362-23-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447362/000144736223000007/cstl-20230108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001447362-23-000007
- JSON: https://secwatch.observer/filing/0001447362-23-000007.json
- Plain text: https://secwatch.observer/filing/0001447362-23-000007.txt

## Key facts
- Earnings Releases
  CASTLE BIOSCIENCES INC updated its the year ended December 31, 2022 guidance (reaffirmed).
  - Period: the year ended December 31, 2022
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: The Company expects to meet or exceed the top end of its previously guided range of $132–137 million for full-year 2022 total revenue.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1447362/000144736223000007/0001447362-23-000007-index.htm
- Earnings Releases
  CASTLE BIOSCIENCES INC reported preliminary financial results for the fourth quarter of 2022.
  - Period: the fourth quarter of 2022
  - Result: preliminary results
  source text: On January 8, 2023, Castle Biosciences, Inc. (the “Company”) issued a press release announcing certain preliminary performance results for the fourth quarter of 2022 and for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1447362/000144736223000007/0001447362-23-000007-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.